Gonda Vascular Center, Mayo Clinic, Rochester, MN; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
Evidence-based Practice Center and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN.
Mayo Clin Proc. 2020 Nov;95(11):2467-2486. doi: 10.1016/j.mayocp.2020.08.030. Epub 2020 Aug 31.
A higher risk of thrombosis has been described as a prominent feature of coronavirus disease 2019 (COVID-19). This systematic review synthesizes current data on thrombosis risk, prognostic implications, and anticoagulation effects in COVID-19. We included 37 studies from 4070 unique citations. Meta-analysis was performed when feasible. Coagulopathy and thrombotic events were frequent among patients with COVID-19 and further increased in those with more severe forms of the disease. We also present guidance on the prevention and management of thrombosis from a multidisciplinary panel of specialists from Mayo Clinic. The current certainty of evidence is generally very low and continues to evolve.
血栓形成风险较高已被描述为 2019 年冠状病毒病（COVID-19）的一个显著特征。本系统评价综合了当前关于 COVID-19 中血栓形成风险、预后意义和抗凝效果的数据。我们纳入了 37 项研究，来自 4070 项独特的引文。当可行时进行了荟萃分析。COVID-19 患者中经常出现凝血功能障碍和血栓形成事件，并且在疾病更严重形式的患者中进一步增加。我们还介绍了 Mayo 诊所多学科专家小组关于血栓形成预防和管理的指南。目前证据的确定性通常非常低，并且还在不断发展。
